[go: up one dir, main page]

MX2008014004A - 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes. - Google Patents

1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.

Info

Publication number
MX2008014004A
MX2008014004A MX2008014004A MX2008014004A MX2008014004A MX 2008014004 A MX2008014004 A MX 2008014004A MX 2008014004 A MX2008014004 A MX 2008014004A MX 2008014004 A MX2008014004 A MX 2008014004A MX 2008014004 A MX2008014004 A MX 2008014004A
Authority
MX
Mexico
Prior art keywords
carboxamides
benzimidazole
substituted
parp inhibitors
potent parp
Prior art date
Application number
MX2008014004A
Other languages
English (en)
Inventor
Jianchun Gong
Virajkumar B Gandhi
Thomas D Penning
Sheela A Thomas
Vincent L Giranda
Gui-Dong Zhu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2008014004A publication Critical patent/MX2008014004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a 1H-benzimidazol-4-carboxamidas de la fórmula (I), su preparación, y su uso como inhibidores de la enzima poli(ADP-ribosa)polimerasa para la preparación de fármacos.
MX2008014004A 2006-05-02 2007-05-02 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes. MX2008014004A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79666306P 2006-05-02 2006-05-02
PCT/US2007/067991 WO2007131016A2 (en) 2006-05-02 2007-05-02 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors

Publications (1)

Publication Number Publication Date
MX2008014004A true MX2008014004A (es) 2008-11-12

Family

ID=38668505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008014004A MX2008014004A (es) 2006-05-02 2007-05-02 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.

Country Status (9)

Country Link
US (2) US20070259937A1 (es)
EP (1) EP2012780B1 (es)
JP (1) JP5228237B2 (es)
CN (1) CN101511821B (es)
AT (1) ATE553104T1 (es)
CA (1) CA2647373C (es)
ES (1) ES2385849T3 (es)
MX (1) MX2008014004A (es)
WO (1) WO2007131016A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
WO2006110683A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
EP1957477B1 (en) * 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
CA2628461C (en) * 2005-11-15 2013-09-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
AU2007232297B2 (en) * 2006-04-03 2012-09-20 Msd Italia S.R.L. Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2012780B1 (en) * 2006-05-02 2012-04-11 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
EP2805945B1 (en) * 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
ES2548131T3 (es) * 2008-01-08 2015-10-14 Merck Sharp & Dohme Limited Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2010115736A2 (en) * 2009-04-02 2010-10-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
WO2012096813A1 (en) * 2011-01-11 2012-07-19 Merck Sharp & Dohme Corp. Imidazole derivatives
CN103242273B (zh) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN102627610B (zh) * 2012-04-11 2014-06-25 江苏先声药物研究有限公司 一类苯并咪唑类衍生物及其应用
US9346743B2 (en) 2012-10-15 2016-05-24 Albemarle Corporation Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
CN104003979B (zh) * 2013-02-21 2016-08-17 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪类化合物、其药物组合物及其制备方法和用途
CN104230896A (zh) * 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
CN113330007A (zh) 2018-10-03 2021-08-31 特沙诺有限公司 尼拉帕利游离碱的晶体形式

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1354554A (en) 1970-08-31 1974-06-05 Robins Co Inc A H 2-substituted benzimidazoles
BE789679A (fr) * 1971-10-05 1973-04-04 Leo Pharm Prod Ltd Nouveaux derives d'acide amino-5 isophtalique et leurs procedesde preparation
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
TR199800127T1 (xx) 1995-08-02 1998-04-21 Newcastle University Ventures Limited Benzimidazol bile�ikleri.
EP0934307B1 (en) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
EP0927167A1 (en) 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
AU6691498A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
AU755694B2 (en) * 1998-11-17 2002-12-19 Basf Aktiengesellschaft 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
ES2216625T3 (es) * 1998-11-27 2004-10-16 ABBOTT GMBH & CO. KG Bencimidazoles substituidos y su empleo como inhibidores de parp.
DE19916460B4 (de) 1999-04-12 2006-12-21 Abbott Gmbh & Co. Kg Substituierte Benzimidazole, deren Herstellung und Anwendung
DE19918211A1 (de) * 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
DE10021468A1 (de) 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
WO2002068407A1 (en) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole compound
US7166292B2 (en) * 2001-06-29 2007-01-23 The Procter & Gamble Company Top-biased beneficial components on substrates
WO2003020698A2 (en) 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
JP2005530763A (ja) 2002-05-13 2005-10-13 アイシーエージェン，インコーポレイティド カリウム・チャネル調節物質としてのビス−ベンズイミダゾール及び関連化合物
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
JP2006514951A (ja) 2002-12-13 2006-05-18 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
EP1590333A4 (en) 2003-01-23 2008-04-30 Crystalgenomics Inc GLYCOGENE SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR PREPARING THE SAME
HU0301154D0 (en) 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
WO2006110683A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP1957477B1 (en) * 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
CA2628461C (en) * 2005-11-15 2013-09-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20090029966A1 (en) * 2006-01-17 2009-01-29 Abbott Laboratories Combination therapy with parp inhibitors
US20080280867A1 (en) * 2006-01-17 2008-11-13 Abbott Laboratories Combination therapy with parp inhibitors
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
CN101370497B (zh) * 2006-01-17 2010-11-17 雅培制药有限公司 包含parp抑制剂和细胞毒性剂的联合产品及用途
US20080293795A1 (en) * 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
EP2012780B1 (en) * 2006-05-02 2012-04-11 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors

Also Published As

Publication number Publication date
CN101511821B (zh) 2013-07-17
EP2012780A4 (en) 2009-06-24
US20070259937A1 (en) 2007-11-08
CA2647373C (en) 2014-03-18
EP2012780A2 (en) 2009-01-14
CN101511821A (zh) 2009-08-19
WO2007131016A3 (en) 2008-12-18
WO2007131016A2 (en) 2007-11-15
ATE553104T1 (de) 2012-04-15
EP2012780B1 (en) 2012-04-11
US20090186877A1 (en) 2009-07-23
ES2385849T3 (es) 2012-08-01
JP2009535427A (ja) 2009-10-01
CA2647373A1 (en) 2007-11-15
JP5228237B2 (ja) 2013-07-03
US7999117B2 (en) 2011-08-16

Similar Documents

Publication Publication Date Title
EP2012780A4 (en) SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES AS POTENTE PARP HEMMER
WO2007149907A3 (en) Pyrazoloquinazolinones as parp inhibitors
MY148634A (en) Pyridazinone derivatives
WO2010111626A3 (en) Poly (adp-ribose) polymerase (parp) inhibitors
WO2007125103A3 (en) Benzamide glucokinase activators
WO2008049116A3 (en) Substituted indoles
ZA200807274B (en) Novel pyridine derivatives
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
WO2008107478A8 (en) Quinolinone derivatives as parp and tank inhibitors
MX360970B (es) Compuestos de heteroarilo y usos de los mismos.
WO2009156462A3 (en) Organic compounds
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2007089768A3 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
MY153921A (en) Aminopyrazole derivatives
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
TW200740814A (en) Compounds
WO2009094457A3 (en) Substituted benzhydrylethers
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2010077730A3 (en) Indanone inhibitors of acetylcholinesterase
WO2008098143A3 (en) Antimicrobial compounds and methods of use
WO2010059639A3 (en) Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights